Global Targeted Protein Degradation Market Size, Share, Growth Analysis, By Application(Small Molecule drug discovery, protein discovery), By Technology(PROTACs (Proteolysis-Targeting Chimeras), LYTACs (Lysosome-Targeting Chimeras)), By Therapeutic area(Oncology, immunology), By Indication(Breast cancer, lung cancer) - Industry Forecast 2024-2031

Name: Global Targeted Protein Degradation Market Size, Share, Growth Analysis, By Application(Small Molecule drug discovery, protein discovery), By Technology(PROTACs (Proteolysis-Targeting Chimeras), LYTACs (Lysosome-Targeting Chimeras)), By Therapeutic area(Oncology, immunology), By Indication(Breast cancer, lung cancer) - Industry Forecast 2023-2030
Brand: SkyQuest Technology
Price: 5300 USD
Availability: InStock

Report ID: SQMIG35H2045 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 121 | Figures: 78

Global Targeted Protein Degradation Market Insights

Targeted Protein Degradation Market size was valued at USD 400.5 million in 2021 and is poised to grow from USD 507.0 million in 2022 to USD 3,300.0 million by 2030, growing at a CAGR of 26.4% in the forecast period (2023-2030).

Targeted Protein Degradation is becoming popular since It is a relatively new approach to drug development that involves using small molecules to selectively eliminate disease causing proteins. It is considered that this approach has several advantages over traditional drug development methods. These advantages include broad applicability, greater selectivity, increased durability, potential for combination therapy, novel mode of action.

Targeted protein degradation is a cutting-edge approach to drug development that offers several potential advantages over conventional methods. One of the key advantages of targeted protein degradation is its broad applicability, allowing it to target a wide range of disease-causing proteins. This includes proteins that have previously been considered "undruggable" using traditional methods. The ability to target a wider range of proteins offers potential new treatments for a variety of diseases, including cancer and genetic disorders. By selectively degrading the specific proteins that cause disease, targeted protein degradation can potentially provide a more effective and specific treatment compared to traditional methods that target entire cells or tissues.

Moreover, the selectivity of targeted protein degradation is a significant advantage. Unlike traditional drugs that can have non-specific effects on cells or tissues, targeted protein degradation can specifically degrade only disease-causing proteins without affecting normal proteins. This reduces the risk of side effects and improves therapeutic efficacy. Another potential advantage of targeted protein degradation is the increased durability of the treatment. Targeted protein degraders can remain active in the body for longer periods of time than traditional drugs, resulting in prolonged therapeutic effects. This may reduce the frequency of dosing, improve patient compliance, and ultimately lead to better patient outcomes.

US Targeted Protein Degradation Market is poised to grow at a sustainable CAGR for the next forecast year.

Global Targeted Protein Degradation Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

It is considered that the competition within the global Targeted Protein Degradation market will intensify during the forecast period. This can be attributed to the entry of new players into the market and the increasing number of developments that are compatible with Targeted Protein Degradation. Presently, only a few major players are operating within the global market. However, this scenario is expected to change in the forthcoming years as more companies are likely to enter the market and offer their services.As the potential of Targeted Protein Degradation for the development of effective therapies for various diseases is becoming increasingly evident, there is a growing interest in this field. This has led to the entry of new players into the market, ranging from small startups to large pharmaceutical companies. With the increasing investments being made in research and development activities, more companies are expected to enter the market and offer their services, resulting in an intensified competitive landscape. Moreover, the growing number of developments compatible with Targeted Protein Degradation is expected to further increase the competition in the market. As more discoveries are made regarding the efficacy of this approach, it is expected to attract more companies, researchers, and investors to this field, thereby increasing the competition. 'Arvinas, Inc.', 'Bayer AG', 'C4 Therapeutics, Inc.', 'Cellestia Biotech AG', 'Cullgen Inc.', 'Cyrus Biotechnology, Inc.', 'Daiichi Sankyo Co., Ltd.', 'Kymera Therapeutics, Inc.', 'Mirati Therapeutics, Inc.', 'Nurix Therapeutics, Inc.', 'Peptidream Inc.', 'Progenra Inc.', 'Proteolix, Inc.', 'Sanofi S.A.', 'Shield Therapeutics, Inc.', 'Syros Pharmaceuticals, Inc.', 'Takeda Pharmaceutical Company Limited', 'Vivace Therapeutics, Inc.', 'Xencor, Inc.', 'Zenith Epigenetics Ltd.', 'In January 2022, Salarius Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing novel treatments for sarcomas, pediatric cancers, and other cancers, entered into a definitive agreement with DeuteRx. As per the agreement, Salarius will acquire an oral, small molecule portfolio for targeted protein degradation, including a lead drug candidate previously known as DRX-164, which Salarius has renamed as SP-3164. The acquisition also includes the related patent family, which includes issued composition of matter patents, as well as the opportunity to develop additional cancer-fighting assets in the targeted protein degradation space.'

The market for targeted protein degradation is being driven by several factors, one of which is the high demand for more effective treatments for a variety of diseases. Diseases such as cancer, genetic disorders, and autoimmune diseases have a significant impact on patient health and quality of life, and there is a growing need for treatments that can address the underlying causes of these diseases. Targeted protein degradation has the potential for selectively targeting disease-causing proteins, which could result in more effective treatments with fewer side effects. This approach allows for the development of drugs that can specifically target the proteins responsible for disease while sparing healthy cells and tissues. This high degree of specificity could potentially reduce the risk of side effects and improve patient outcomes. Moreover, the ability to selectively target disease-causing proteins provides a potential solution for previously untreatable diseases, including those that have been considered "undruggable" using traditional methods. This creates new opportunities for drug development and offers hope for patients with few treatment options.

One of the notable trends in the targeted protein degradation market is the growing emphasis on the development of oral drugs. This trend is driven by the increasing demand for more patient-friendly therapies that offer greater convenience and compliance. Oral drugs have a significant advantage over other forms of drug delivery, such as injections or infusions, as they can be easily taken at home and do not require patients to visit hospitals or clinics for treatment. To address this trend, several pharmaceutical companies are investing heavily in the research and development of oral drugs for targeted protein degradation. They are developing drugs that are capable of surviving the digestive tract and reaching the intended targets in the body. These drugs can also be formulated to release slowly in the body, ensuring a sustained therapeutic effect. The development of oral drugs for targeted protein degradation is expected to have a significant impact on patient care and drug development in the coming years. With these drugs, patients can receive effective treatment for a range of diseases from the comfort of their own homes, without the need for frequent hospital visits. Furthermore, the development of oral drugs is expected to increase patient compliance, which is critical for the success of any therapeutic intervention.

The targeted protein degradation market is currently dominated by North America, which holds the largest market share. This is attributed to the presence of numerous pharmaceutical and biotechnology companies in the region, as well as substantial investment in research and development activities.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Global Targeted Protein Degradation Market Insights

Global Targeted Protein Degradation Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of Targeted Protein Degradation Market?

Who are the key vendors in the Global Targeted Protein Degradation Market?

What is the key driver of Global Targeted Protein Degradation Market?

What is the key market trend for Global Targeted Protein Degradation Market?

Which region accounted for the largest share in Global Targeted Protein Degradation Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300